NASDAQ:EXAI Exscientia (EXAI) Stock Forecast, Price & News $5.17 +0.28 (+5.73%) (As of 09/22/2023 08:51 PM ET) Add Compare Share Share Today's Range$4.88▼$5.2750-Day Range$4.53▼$8.9052-Week Range$4.09▼$11.52Volume709,100 shsAverage Volume1.00 million shsMarket Capitalization$625.00 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Exscientia MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside151.5% Upside$13.00 Price TargetShort InterestBearish1.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.32) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector757th out of 961 stocksBiological Products, Except Diagnostic Industry120th out of 159 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Exscientia has a forecasted upside of 151.5% from its current price of $5.17.Amount of Analyst CoverageExscientia has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.95% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Exscientia has recently increased by 13.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 2.5 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Exscientia this week, compared to 1 article on an average week.Search Interest18 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Institutions42.68% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to decrease in the coming year, from ($1.32) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exscientia (NASDAQ:EXAI) StockExscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comExscientia (NASDAQ:EXAI) Sees Unusually-High Trading VolumeSeptember 21, 2023 | markets.businessinsider.comFedEx, Splunk, FactSet Research And Other Big Stocks Moving Higher On ThursdaySeptember 25, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 21, 2023 | finance.yahoo.comDown -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a TurnaroundSeptember 20, 2023 | thestreet.comExscientia PlcSeptember 20, 2023 | markets.businessinsider.comExscientia Shares Surge On AI Collaboration: The DetailsSeptember 20, 2023 | seekingalpha.comExscientia: Merck Deal Further Cements Industry Positioning, Reiterate BuySeptember 20, 2023 | marketwatch.comExscientia Shares Rally Premarket on Lucrative Merck Deal >EXAISeptember 25, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 20, 2023 | finance.yahoo.comExscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, GermanyAugust 31, 2023 | finance.yahoo.comBroker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging HigherAugust 12, 2023 | finance.yahoo.comExscientia plc (NASDAQ:EXAI) Analysts Just Trimmed Their Revenue Forecasts By 25%August 11, 2023 | markets.businessinsider.comExscientia Plc (EXAI) Receives a Buy from BarclaysAugust 10, 2023 | finance.yahoo.comExscientia Business Update for Second Quarter and First Half of 2023August 3, 2023 | finance.yahoo.comExscientia to Report Second Quarter 2023 Financial Results on August 10, 2023August 2, 2023 | theglobeandmail.comInstrument Name Exscientia Ltd ADR Instrument Symbol (EXAI-Q)August 1, 2023 | msn.comExscientia Is Worth The AI-Driven SpeculationJuly 21, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Meaningful Upgrade To Their Exscientia plc (NASDAQ:EXAI) ForecastsJuly 20, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for ExscientiaJuly 18, 2023 | finance.yahoo.comExscientia Initiates Prospective Observational Study in Ovarian CancerJuly 13, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Technology Companies: Endava (DAVA) and Exscientia Plc (EXAI)July 12, 2023 | finance.yahoo.comWhy Shares of Exscientia Jumped on WednesdayJuly 10, 2023 | benzinga.comGT Apeiron Announces Enrollment of First Patient in Phase 1/2 "ELUCIDATE" Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid TumorsJuly 10, 2023 | finance.yahoo.comFirst Patient Enrolled in Phase 1/2 "ELUCIDATE" Trial Assessing GTAEXS617 in Advanced Solid TumoursJune 29, 2023 | finance.yahoo.comWe're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn RateJune 29, 2023 | finance.yahoo.comExscientia Announces Expansion of its Technology Leadership TeamJune 28, 2023 | msn.comCullinan Oncology: Playing 'Moneyball' In The Drug Development SectorSee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAI Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees481Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+151.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,850,000.00 Net Margins-685.82% Pretax Margin-810.00% Return on Equity-31.67% Return on Assets-23.59% Debt Debt-to-Equity Ratio0.04 Current Ratio6.88 Quick Ratio6.88 Sales & Book Value Annual Sales$32.90 million Price / Sales19.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.82 per share Price / Book1.07Miscellaneous Outstanding Shares120,890,000Free Float101,062,000Market Cap$625.00 million OptionableNot Optionable Beta0.55 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesProf. Andrew L. Hopkins DPHIL (Age 50)FMEDSCI, FRSE FRSC, Founder, CEO & Exec. Director Comp: $682.34kMr. Ben R. Taylor (Age 46)CFO, Chief Strategy Officer & Exec. Director Comp: $478.29kDr. David Hallett Ph.D. (Age 52)Chief Scientific Officer Dr. Garry Pairaudeau Ph.D. (Age 57)Advisor Dr. Michael Krams M.D. (Age 62)Chief Quantitative Medicine Officer Ms. Eileen Jennings-BrownChief Information OfficerMr. Dan IrelandVP of Legal & Company Sec.Ms. Caroline RowlandChief People OfficerMr. Richard LawChief Bus. OfficerProf. Charlotte Deane M.B.E.Ph.D., Chief AI OfficerMore ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTAnavex Life SciencesNASDAQ:AVXLEditas MedicineNASDAQ:EDITAllogene TherapeuticsNASDAQ:ALLOHilleVaxNASDAQ:HLVXView All CompetitorsInstitutional OwnershipWoodline Partners LPBought 144,691 shares on 8/15/2023Ownership: 0.635%Point72 Asset Management L.P.Bought 579,500 shares on 8/15/2023Ownership: 0.479%Wells Fargo & Company MNSold 26,288 shares on 8/15/2023Ownership: 0.214%Citadel Advisors LLCSold 3,300 shares on 8/15/2023Ownership: 0.000%Pivotal bioVenture Partners Investment Advisor LLCSold 1,785 shares on 8/11/2023Ownership: 0.637%View All Institutional Transactions EXAI Stock - Frequently Asked Questions Should I buy or sell Exscientia stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks. What is Exscientia's stock price forecast for 2023? 3 equities research analysts have issued 12-month price objectives for Exscientia's shares. Their EXAI share price forecasts range from $12.00 to $14.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 151.5% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts. How have EXAI shares performed in 2023? Exscientia's stock was trading at $5.33 on January 1st, 2023. Since then, EXAI stock has decreased by 3.0% and is now trading at $5.17. View the best growth stocks for 2023 here. Are investors shorting Exscientia? Exscientia saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,280,000 shares, an increase of 13.4% from the August 15th total of 2,010,000 shares. Based on an average daily volume of 339,000 shares, the short-interest ratio is currently 6.7 days. Currently, 2.0% of the company's shares are sold short. View Exscientia's Short Interest. When is Exscientia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our EXAI earnings forecast. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) posted its earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.04. The company earned $3.80 million during the quarter, compared to analysts' expectations of $16.27 million. Exscientia had a negative net margin of 685.82% and a negative trailing twelve-month return on equity of 31.67%. What ETFs hold Exscientia's stock? ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did Exscientia IPO? (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. What is Exscientia's stock symbol? Exscientia trades on the NASDAQ under the ticker symbol "EXAI." Who are Exscientia's major shareholders? Exscientia's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.20%), Platinum Investment Management Ltd. (3.30%), Pivotal bioVenture Partners Investment Advisor LLC (0.64%), Woodline Partners LP (0.63%), BlackRock Inc. (0.57%) and Point72 Asset Management L.P. (0.48%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exscientia's stock price today? One share of EXAI stock can currently be purchased for approximately $5.17. How much money does Exscientia make? Exscientia (NASDAQ:EXAI) has a market capitalization of $625.00 million and generates $32.90 million in revenue each year. The company earns $-146,850,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. How many employees does Exscientia have? The company employs 481 workers across the globe. How can I contact Exscientia? The official website for the company is www.exscientia.ai. The company can be reached via phone at 44-0-18-6581-8941 or via email at investors@exscientia.ai. This page (NASDAQ:EXAI) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.